These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30453728)

  • 61. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
    Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
    Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
    Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
    J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
    J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.
    Wahner Hendrickson AE; Hawthorne KM; Goode EL; Kalli KR; Goergen KM; Bakkum-Gamez JN; Cliby WA; Keeney GL; Visscher DW; Tarabishy Y; Oberg AL; Hartmann LC; Maurer MJ
    Gynecol Oncol; 2015 Apr; 137(1):77-85. PubMed ID: 25620544
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma.
    Ha Y; Han S; Shim JH; Ko GY; Yoon HK; Sung KB; Lee D; Kim KM; Lim YS; Chung YH; Lee YS; Lee HC
    J Vasc Interv Radiol; 2015 Aug; 26(8):1093-1101.e1. PubMed ID: 26077020
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
    J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
    Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
    Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
    Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
    Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
    [TBL] [Abstract][Full Text] [Related]  

  • 71. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
    Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
    Krasner CN; Castro C; Penson RT; Roche M; Matulonis UA; Morgan MA; Drescher C; Armstrong DK; Wolfe JK; Lee H; Supko JG; Seiden M; Birrer MJ; Dizon DS
    Gynecol Oncol; 2019 May; 153(2):223-229. PubMed ID: 30765148
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).
    Farolfi A; Petrone M; Scarpi E; Gallà V; Greco F; Casanova C; Longo L; Cormio G; Orditura M; Bologna A; Zavallone L; Ventriglia J; Franzese E; Loizzi V; Giardina D; Pigozzi E; Cioffi R; Pignata S; Giorda G; De Giorgi U
    Target Oncol; 2018 Aug; 13(4):469-479. PubMed ID: 29948780
    [TBL] [Abstract][Full Text] [Related]  

  • 74. GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.
    Zhao D; Wang X; Zhang W
    BMC Cancer; 2018 Mar; 18(1):328. PubMed ID: 29580231
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
    Mardas M; Stelmach-Mardas M; Madry R
    Support Care Cancer; 2017 Mar; 25(3):795-800. PubMed ID: 27771784
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Risk predictors of early recurrence in women with epithelial ovarian cancer in Lagos, Nigeria.
    Okunade KS; Adetuyi IE; Adenekan M; Ohazurike E; Anorlu RI
    Pan Afr Med J; 2020; 36():272. PubMed ID: 33088401
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
    Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
    Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Enhancing precision medicine: a nomogram for predicting platinum resistance in epithelial ovarian cancer.
    Li R; Xiong Z; Ma Y; Li Y; Yang Y; Ma S; Ha C
    World J Surg Oncol; 2024 Mar; 22(1):81. PubMed ID: 38509620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.